

WHO Drug Information

Contents

Quality Assurance Issues

Good pharmaceutical trade and distribution practices 1

Personal Perspectives

Risk assessment as an element of drug control 6

Current Topics

The WHO Model List of Essential Drugs: latest developments 12

Sequencing of the *Anopheles gambiae* genome 14

Multilateral initiative on Malaria: benefits to the global community 15

China revises its pharmaceutical law 16

Regulatory and Safety Matters

New formulation of DTP vaccine 17

Bupropion safety reminder 17

Propofol: reactions to long-term high doses 17

Propofol: not for paediatric use 18

Leflunomide: hepatic reactions 18

Rapacuronium bromide voluntarily withdrawn 18

Levacetylmethadol withdrawn 19

Levacetylmethadol: labelling changes 19

Isotretinoin and depression 19

New glucose test for adult diabetics 19

Anti-inflammatory analgesics: hepatic reactions 20

Gentamicin ear drops: toxicity 20

Tetracycline and benign intracranial hypertension 20

Ergotamine and erythromycin interaction 21

Celecoxib and warfarin interaction 21

Cerivastatin: rare effect of rhabdomyolysis 22

SSRIs and increased ocular pressure 22

Amfepramone: new cases of primary pulmonary hypertension 23

Bufexamac and contact eczema 23

Droperidol: prolongation of the QT interval 23

Mofezolac: revised data sheet 24

Monoethanolamine oleate: revised data sheet 24

Rivastigmine: revised product information 24

Sarpogrelate: revised data sheet 25

ATC/DDD Classification

ATC/DDD methodology: a country perspective 26

Recommended International 31

Nonproprietary Names: List 45

Printed in Malta
2001/13910 - Interprint - 5300